Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) Study (vol 27, pg 509, 2009)

被引：0

|

作者：

Bousser, M. G.

Amarenco, P.

Chamorro, A.

机构：

来源：

CEREBROVASCULAR DISEASES | 2017年 / 43卷 / 3-4期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：206 / 206

页数：1

相关论文

共 11 条

[1] Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study
Bousser, M. G.
Amarenco, P.
Chamorro, A.
Fisher, M.
Ford, I.
Fox, K.
Hennerici, M. G.
Mattle, H. P.
Rothwell, P. M.
CEREBROVASCULAR DISEASES, 2009, 27 (05) : 509 - 518
[2] Rationale and Design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study
Hennerici, Michael G.
CEREBROVASCULAR DISEASES, 2009, 27 : 28 - 32
[3] The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline Characteristics of the Population
Bousser, M. G.
Amarenco, P.
Chamorro, A.
Fisher, M.
Ford, I.
Fox, K.
Hennerici, M.
Mattle, H. P.
Rothwell, P. M.
CEREBROVASCULAR DISEASES, 2009, 27 (06) : 608 - 613
[4] Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
Michael G. Hennerici
Michiel L. Bots
Ian Ford
Stéphane Laurent
Pierre Jean Touboul
Cardiovascular Drugs and Therapy, 2010, 24 : 175 - 180
[5] Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
Hennerici, Michael G.
Bots, Michiel L.
Ford, Ian
Laurent, Stephane
Touboul, Pierre Jean
CARDIOVASCULAR DRUGS AND THERAPY, 2010, 24 (02) : 175 - 180
[6] Heart rate is a prognostic risk factor formyocardial infarction: A post hoc analysis in the PERFORM ( Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population
Fox, Kim
Bousser, Marie-Germaine
Amarenco, Pierre
Chamorro, Angel
Fisher, Marc
Ford, Ian
Hennerici, Michael G.
Mattle, Heinrich P.
Rothwell, Peter M.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (04) : 3500 - 3505
[7] Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial (vol 377, pg 2013, 2011)
Bousser, M-G
Amarenco, P.
Chamorro, A.
LANCET, 2011, 378 (9789): : 402 - 402
[8] Rationale and design to assess the efficacy and safety of HT047 in patients with acute ischemic stroke A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase II trial
Heo, Sung Hyuk
Song, Jungbin
Kim, Bum Joon
Kim, Hocheol
Chang, Dae-Il
MEDICINE, 2019, 98 (43)
[9] Design of the LEGATO-HD study: A multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquinimod (0.5, 1.0 and 1.5 mg/day) as treatment in patients with Huntington's disease
Reilmann, R.
Tabrizi, S.
Leavitt, B.
Stout, J. C.
Piccini, P.
Anderson, K. E.
Feigin, A.
Hayden, M.
Grozinski-Wolff, M.
Eyal, E.
Wickenberg, A.
MOVEMENT DISORDERS, 2015, 30 : S537 - S537
[10] Efficacy and Safety of Olmesartan Medoxomil 40 mg/Hydrochlorothiazide 12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Moderate to Severe Hypertension A Randomized, Double-Blind, Parallel-Group, Multicentre, Multinational, Phase III Study (vol 30, pg 581, 2010)
Fogari, Roberto
Taddei, Stefano
Holm-Bentzen, Merete
Baszak, Jacek
Melani, Lorenzo
Schumacher, Kai
CLINICAL DRUG INVESTIGATION, 2013, 33 (01) : 95 - 95